Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
South Korea · Delayed Price · Currency is KRW 68,700
+5,700 (9.05%)
Oct 10, 2025, 3:30 PM KST
Mezzion Pharma Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | 7,883 | 8,612 | 31,721 | 30,726 | 26,654 | 28,634 | Upgrade |
Other Revenue | -0 | -0 | -0 | - | - | - | Upgrade |
| 7,883 | 8,612 | 31,721 | 30,726 | 26,654 | 28,634 | Upgrade | |
Revenue Growth (YoY) | -61.07% | -72.85% | 3.24% | 15.28% | -6.92% | 59.78% | Upgrade |
Cost of Revenue | 6,272 | 6,701 | 27,836 | 31,040 | 22,956 | 21,196 | Upgrade |
Gross Profit | 1,610 | 1,910 | 3,884 | -313.44 | 3,698 | 7,438 | Upgrade |
Selling, General & Admin | 13,033 | 14,958 | 16,142 | 19,510 | 17,283 | 12,857 | Upgrade |
Research & Development | 294.04 | 294.04 | 938.97 | 2,217 | 1,956 | 937.56 | Upgrade |
Operating Expenses | 14,311 | 16,210 | 18,373 | 23,018 | 20,496 | 14,969 | Upgrade |
Operating Income | -12,700 | -14,300 | -14,489 | -23,331 | -16,798 | -7,531 | Upgrade |
Interest Expense | -350.25 | -300.79 | -315.46 | -423.44 | -323.41 | -320.21 | Upgrade |
Interest & Investment Income | 871.52 | 1,431 | 1,477 | 763.35 | 306.23 | 357.47 | Upgrade |
Currency Exchange Gain (Loss) | -6,337 | 286.56 | 996.94 | 3,177 | 3,700 | -2,460 | Upgrade |
Other Non Operating Income (Expenses) | -1,426 | -1,180 | -157.21 | -1,410 | 90.67 | 57.43 | Upgrade |
EBT Excluding Unusual Items | -19,942 | -14,062 | -12,488 | -21,225 | -13,025 | -9,895 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | - | - | - | 26.76 | Upgrade |
Gain (Loss) on Sale of Assets | -426.95 | -471.69 | 7.35 | 8.99 | -1.08 | -23.92 | Upgrade |
Asset Writedown | - | - | - | -14,694 | - | -2,944 | Upgrade |
Pretax Income | -20,368 | -14,534 | -12,480 | -35,910 | -13,026 | -12,836 | Upgrade |
Income Tax Expense | 2,722 | 4,943 | 248.07 | 388.23 | 577.06 | 1,036 | Upgrade |
Earnings From Continuing Operations | -23,090 | -19,477 | -12,728 | -36,298 | -13,603 | -13,873 | Upgrade |
Earnings From Discontinued Operations | - | - | - | - | - | 43.53 | Upgrade |
Net Income | -23,090 | -19,477 | -12,728 | -36,298 | -13,603 | -13,829 | Upgrade |
Net Income to Common | -23,090 | -19,477 | -12,728 | -36,298 | -13,603 | -13,829 | Upgrade |
Shares Outstanding (Basic) | 30 | 30 | 28 | 27 | 27 | 26 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 28 | 27 | 27 | 26 | Upgrade |
Shares Change (YoY) | 0.97% | 5.62% | 5.63% | 0.17% | 2.63% | 0.11% | Upgrade |
EPS (Basic) | -770.43 | -653.04 | -450.74 | -1357.81 | -509.70 | -531.83 | Upgrade |
EPS (Diluted) | -770.43 | -653.04 | -451.00 | -1358.00 | -510.00 | -531.99 | Upgrade |
Free Cash Flow | -10,815 | -19,080 | -11,553 | -12,842 | -15,429 | -8,151 | Upgrade |
Free Cash Flow Per Share | -360.85 | -639.74 | -409.10 | -480.39 | -578.14 | -313.46 | Upgrade |
Gross Margin | 20.43% | 22.18% | 12.25% | -1.02% | 13.88% | 25.98% | Upgrade |
Operating Margin | -161.12% | -166.05% | -45.67% | -75.93% | -63.02% | -26.30% | Upgrade |
Profit Margin | -292.93% | -226.17% | -40.13% | -118.13% | -51.03% | -48.30% | Upgrade |
Free Cash Flow Margin | -137.20% | -221.56% | -36.42% | -41.80% | -57.89% | -28.47% | Upgrade |
EBITDA | -11,717 | -13,342 | -12,942 | -21,673 | -15,212 | -6,098 | Upgrade |
EBITDA Margin | -148.64% | -154.93% | -40.80% | -70.54% | -57.07% | -21.30% | Upgrade |
D&A For EBITDA | 983.46 | 957.8 | 1,546 | 1,658 | 1,586 | 1,432 | Upgrade |
EBIT | -12,700 | -14,300 | -14,489 | -23,331 | -16,798 | -7,531 | Upgrade |
EBIT Margin | -161.12% | -166.05% | -45.67% | -75.93% | -63.02% | -26.30% | Upgrade |
Updated Mar 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.